Immunitas Therapeutics is a single cell genomics-based drug discovery company that employs a single cell genomics platform to dissect the biology of immune cells in human tumors, thereby advancing discoveries directly from the bench into meaningful clinical improvements.
Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers.
Immunitas Therapeutics was founded in 2019 by (Longwood Fund) Kai Wucherpfennig, Mario Suvà, & Dane Wittrup. The company is based in Boston, Massachusetts.
Immunitas was founded to directly address the challenge of translating findings from laboratory research in model organisms to meaningful clinical advances in humans.
Immunitas focuses on human samples, allowing the company to start with and stay closer to the most relevant and translatable biology for patients.
The Immunitas platform has generated fully humanized antibodies that act on these targets, advancing to human efficacy studies driven by specific clinical biomarkers, and a breadth of promising druggable cancer targets.
Immunitas Therapeutics is backed by Leaps by Bayer, Novartis Venture Fund, Evotec, M Ventures, Alexandria Venture Investments and others. The company raised $39M from a single Series A financing on Nov 21, 2019.